Lymphangioleiomyomatosis (LAM) as one of the first nationally recognized rare [6], is a multisystem, low-grade malignant neoplastic disease that can be classified into two types: sporadic LAM (S-LAM), which occurs without any known underlying genetic condition, and tuberous sclerosis complex-associated LAM (TSC-LAM), which is linked to mutations in the TSC1 or TSC2 genes [7]. Here, TSC2 is linked to lymphangioleiomyomatosis.